Abstract
We investigated an antiinflammatory effect of rebamipide {2-{4-chlorobenzoylamino}-3-[2(1H)-quinolinon-4-yl] propionic acid}, a gastroprotective agent, in H. pylori-associated gastritis. Eighty-six patients with H. pylori-positive chronic gastritis were enrolled: 53 were treated with rebamipide (300 mg daily for 12 months) and 33 served as controls. Significant decreases in mononuclear cell infiltration into the antrum and corpus were noted in the rebamipide treatment group (before vs after, 1.42 ± 0.15 vs 1.02 ± 0.15; P < 0.01 and 1.60 ± 0.15 vs 1.21 ± 0.14; P < 0.05, respectively). Levels of infiltrating neutrophil were also decreased in the antrum (before vs after, 0.98 ± 0.14 vs 0.70 ± 0.13; P < 0.05) and were associated with a decrease in iNOS production. Sera from patients treated with rebamipide showed a significant decrease in gastrin (276.3 ± 58.3 pg/ml vs 173.0 ± 34.2 pg/ml; P < 0.05), whereas no change was observed in the control group. These suggest that long-term rebamipide treatment improved histologic gastritis and decreased serum gastrin levels in H. pylori-associated gastritis.
Similar content being viewed by others
REFERENCES
Kawaguchi H, Haruma K, Komoto K, Yoshihara M, Sumii K, Kajiyama G: Helicobacter pylori infection is the major risk factor for atrophic gastritis. Am J Gastroenterol 91:959–962, 1996
Correa P: Helicobacter pylori and gastric carcinogenesis. Am J Surg Path 19(suppl 1):S37–S43, 1995
Kohmoto K, Haruma K, Kamada T, Tanaka S, Yoshihara M, Sumii K, Kajiyama G, Talley NJ: Helicobacter pylori infection and gastric neoplasia: correlations with histological gastritis and tumor histology. Am J Gastroenterol 93:1271–1276, 1998
Haruma K, Komoto K, Kamada T, Ito M, Kitadai Y, Yoshihara M, Sumii K, Kajiyama G: Helicobacter pylori is a major risk factor for gastric carcinoma in young patients. Scand J Gastroenterol 35:255–259, 2000
Naito Y, Yoshikawa T, Iinuma S, Yagi N, Matsuyama K, Boku Y, Fujii T, Yoshida N, Kondo M, Sasaki E: Rebamipide protects against indomethacin-induced gastric mucosal injury in healthy volunteers in double-blind, placebo-controlled study. Dig Dis Sci 43:83S–89S, 1998
Nebiki H, Higuchi K, Arakawa T, Ando K, Uchida T, Ito H, Harihara S, Kuroki T, Kobayashi K: Effect of rebamipide on Helicobacter pylori infection in patients with peptic ulcer. Dig Dis Sci 43:203S–206S, 1998
Han BG, Kim HS, Rhee KH, Han HS, Chung MH: Effects of rebamipide on gastric cell damage by Helicobacter pyloristimulated human neutrophils. Pharmacol Res 32:201–207, 1995
Yoshikawa T, Naito Y, Tanigawa T, Kondo M: Free radical scavenging activity of the novel anti-ulcer agent rebamipide studied by electron spin resonanse. Arzneim-Forsch/Drug Res 43:363–366, 1993
Moss SF, Legon S, Davies J, Calam J: Cytokine gene expression in Helicobacter pylori associated antral gastritis. Gut 35:1567–1570, 1994
Noach LA, Bosma NB, Jansen J, Hoek FJ, van Deventer SJ, Tytgat GN: Mucosal tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8 production in patients with Helicobacter pylori infection. Scand J Gastroenterol 29:425–429, 1994
Crabtree JE, Lindley IJ: Mucosal interleukin-8 and Helicobacter pylori-associated gastroduodenal disease. Eur J Gastroenterol Hepatol 6(suppl 1):33S–38S, 1994
Gionchetti P, Vaira D, Campieri M, Holton J, Menegatti M, Belluzzi A, Bertinelli E, Ferretti M, Brignola C, Miglioli M: Enhanced mucosal interleukin-6 and-8 in Helicobacter pylori-positive dyspeptic patients. Am J Gastroenterol 89:883–887, 1994
Sharma SA, Tummuru MK, Millee GG, Blaser MJ: Interleukin-8 response of gastric epithelial cell lines to Helicobacter pylori stimulation in vitro. Infect Immun 63:1681–1687, 1995
Kim H, Seo JY, Kim KH: Inhibition of lipid peroxidation, NF-kappaB activation and IL-8 production by rebamipide in Helicobacter pylori-stimulated gastric epithelial cells. Dig Dis Sci 45:621–628, 2000
Mihara M, Haruma K, Kamada T, Katadai Y, Yanaka S, Yoshihara M, Sumii K, Kajiyama G, Ito H, Ito M, Miyamoto M, Nishida T, Murakami S, Sanuki E, Omoto Y: The relationship between pathologic gastritis and mucosal interleukin-8 levels. Including the effect of rebamipide to mucosal interleukin-8 levels. Shokakika 24:681–688, 1997 (in Japanese)
Dixon MF, Genta RM, Yardley JH, Correa P, and participants: Classification and grading of gastritis. The updated Sydney system. International Workshop on the Histopathology of Gastritis Houston 1994. Am J Surg Pathol 20:1161–1181, 1996
Haruma K, Ito M, Kohmoto K, Kamada T, Kitada Y, Yasui W, Tahara E, Kajiyama G: Expression of cell cycle regulators and growth factor/receptor systems in gastric carcinoma in young adults: association with Helicobacter pylori infection. Int J Mol Med 5:185–190, 2000
Goto T, Haruma K, Kitadai Y, Ito M, Yoshihara M, Sumii K, Hayakawa N, Kajiyama G: Enhanced expression of inducible nitric oxide synthase and nitrotyrosine in gastric mucosa of gastric cancer patients. Clin Cancer Res 5:1411–1415, 1999
The Eurogast Study Group: An international association between Helicobacter pylori infection and gastric cancer. Lancet 341:1359–1362, 1993
International Agency for Research on Cancer: Schistosomes, liver flukes and Helicobacter pylori. Monograph 61, Lyon, France, IARC, 1994
Walsh JH: Cag A protein from Helicobacter pylori is a Trojan horse to epithelial cells. Gastroenterology 118:817–818, 2000
Maeda S, Ogura K, Yoshida H, Kanai F, Ikenoue T, Kato N, Shiratori Y, Omata M: Major virulence factors, Vac A and Cag A, are commonly positive in Helicobacter pylori isolates in Japan. Gut 42:338–343, 1998
Haruma K, Mihara M, Okamoto E, Kusunoki H, Hananoki M, Tanaka S, Yoshihara M, Sumii K, Kajiyama G: Eradication of Helicobacter pylori increases gastric acidity in patients with atrophic gastritis of the corpus. Evaluation of 24-hr pH monitoring. Aliment Pharmacol Ther 13:155–162, 1999
Correa P: A human model of gastric carcinogenesis. Cancer Res 48:3554–3560, 1988
Stamler JS, Singel DJ, Loscalzo J: Biochemistry of nitric oxide and its redox-activated forms. Science 258:1898–1902, 1992
Mannick EE, Bravo LE, Zarama G, Realpe JL, Zhang XJ, Ruiz B, Fontham ET, Mera R, Miller MJ, Correa P: Inducible nitric oxide synthase, nitrotyrosine, and apoptosis in Helicobacter pylori gastritis: Effect of antibiotics and antioxidants. Cancer Res 56:3238–3243, 1996 2
Rajnakova A, Goh PM, Chan ST, Ngoi SS, Alponat A, Moochhala S: Expression of differential nitric oxide synthase isoforms in human normal gastric mucosa and gastric cancer tissue. Carcinogenesis 18:1841–1845, 1997
Hahm KB, Lee KJ, Kim JH, Cho SW, Chung MH: Helicobacter pylori infection, oxidative DNA damage, gastric carcinogenesis, and reversibility by rebamipide. Dig Dis Sci 43(suppl 9):72S–77S, 1998
Nagano C, Wakebe H, Azuma A, Imagawa K, Kikuch M: IFN-gamma-induced iNOS mRNA expression is inhibited by rebamipide in murine macrophage RAW264.7 cells. Dig Dis Sci 43(suppl 9):118S–124S, 1998
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Haruma, K., Ito, M., Kido, S. et al. Long-Term Rebamipide Therapy Improves Helicobacter pylori-Associated Chronic Gastritis. Dig Dis Sci 47, 862–867 (2002). https://doi.org/10.1023/A:1014716822702
Issue Date:
DOI: https://doi.org/10.1023/A:1014716822702